Rituximab Versus Watchful Waiting for Asymptomatic Advanced-Stage Low-Tumor-Burden Follicular Lymphoma: A Systematic Review and Meta-Analysis. (PubMed, Clin Lymphoma Myeloma Leuk) - Oct 8, 2026 - "Early rituximab monotherapy was not associated with improved OS or a significant reduction in HT compared with WW in asymptomatic patients with advanced-stage LTB-FL, although it prolonged TTNT. Further prospective studies are warranted to define the long-term clinical impact of early rituximab."
Journal • Retrospective data • Review • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology
|
|
Akihiro Miyashita; Fahad Alabbas; Henrique Guimarães Barbosa Coelho; Hosana Candreva; Mehak Dang; Yujin Jeong
|